Figure 2.

Achievement of categorical weight loss goals in (A) CONQUER and (B) SEQUEL [27,29]. (A) CONQUER Study, subjects with ≥ 5% or ≥ 10% weight loss at week 56; (B) SEQUEL Study, percentage (95% CI) of subjects achieving ≥ 5, ≥ 10, ≥ 15 or ≥ 20% weight loss from baseline to week 108 (ITT-LOCF).

A. Adapted from Gadde et al. [27]. B. Adapted from Garvey et al. [29].
*p < 0.0001 compared with placebo.
^‡p = 0.0072 compared with placebo.
CI: Confidence interval; ITT-LOCF: Intent-to-treat, last observation carried forward; PHEN/TPM ER: Phentermine/topiramate extended-release.